1. Home
  2. WRLD vs PRTA Comparison

WRLD vs PRTA Comparison

Compare WRLD & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo World Acceptance Corporation

WRLD

World Acceptance Corporation

HOLD

Current Price

$165.81

Market Cap

646.0M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.91

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRLD
PRTA
Founded
1962
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
646.0M
539.9M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
WRLD
PRTA
Price
$165.81
$9.91
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
145.2K
457.3K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.60
Revenue
$564,841,465.00
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
$6.51
N/A
P/E Ratio
N/A
$16.39
Revenue Growth
N/A
N/A
52 Week Low
$110.00
$4.32
52 Week High
$185.48
$11.80

Technical Indicators

Market Signals
Indicator
WRLD
PRTA
Relative Strength Index (RSI) 70.94 47.61
Support Level $163.76 $9.66
Resistance Level $175.82 $10.11
Average True Range (ATR) 5.80 0.63
MACD 1.20 -0.07
Stochastic Oscillator 99.71 30.22

Price Performance

Historical Comparison
WRLD
PRTA

About WRLD World Acceptance Corporation

World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: